New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06400472
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times
Summary
This study tests a new drug called LY4170156 in people with advanced solid tumors, such as ovarian, lung, and pancreatic cancers. The drug is designed to target and kill cancer cells that have a specific marker (folate receptor alpha). The trial has two parts: first, finding the safest dose, and then testing how well it works. About 495 participants will take part, and the study will last up to 4 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGTokyo, 135-8550, Japan
-
Cancer Research SA
RECRUITINGAdelaide, 5000, Australia
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
HonorHealth
RECRUITINGScottsdale, Arizona, 85258, United States
-
Hospital Clinico Universitario de Valencia
RECRUITINGValencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Icon Cancer Centre South Brisbane
RECRUITINGQLD, 4101, Australia
-
Institut de Cancerologie de l'Ouest - site St-Herblain
RECRUITINGSaint-Herblain, 44805, France
-
Istituto Clinico Humanitas
RECRUITINGRozzano, 20089, Italy
-
Istituto Europeo di Oncologia
RECRUITINGMilan, 20141, Italy
-
NYU Langone Health - Long Island
RECRUITINGMineola, New York, 11501, United States
-
National Cancer Center
RECRUITINGGoyang-si Gyeonggi-do, 10408, South Korea
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
New York University (NYU) Clinical Cancer Center
RECRUITINGNew York, New York, 10016, United States
-
Oncopole Claudius Regaud
RECRUITINGToulouse, 31059, France
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Shizuoka Cancer Center
RECRUITINGShizuoka, 411-8777, Japan
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
The Ohio State University (OSU) Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Texas - MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4000, United States
-
University of California, San Diego (UCSD) - Moores Cancer Center
RECRUITINGLa Jolla, California, 92037, United States
Conditions
Explore the condition pages connected to this study.